Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.

Fröhlich, Anne; Hoffmann, Friederike; Niebel, Dennis; Egger, Eva; Kukuk, Guido M; Toma, Marieta; Sirokay, Judith; Bieber, Thomas; Landsberg, Jennifer

Fröhlich, Anne; Hoffmann, Friederike; Niebel, Dennis; Egger, Eva; Kukuk, Guido M; Toma, Marieta; Sirokay, Judith; Bieber, Thomas; Landsberg, Jennifer.

Afiliação

Fröhlich A; Department of Dermatology and Allergy, Rheinische-Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Hoffmann F; Department of Dermatology and Allergy, Rheinische-Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Niebel D; Department of Dermatology and Allergy, Rheinische-Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Egger E; Department of Gynaecology, Rheinische-Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Kukuk GM; Department of Radiology, Kantonsspital Graubünden, Chur, Switzerland.
Toma M; Department of Pathology University Hospital Bonn, Rheinische-Friedrich-Wilhelms -Universität Bonn, Bonn, Germany.
Sirokay J; Department of Dermatology and Allergy, Rheinische-Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Bieber T; Department of Dermatology and Allergy, Rheinische-Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Landsberg J; Department of Dermatology and Allergy, Rheinische-Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.

Front Oncol ; 10: 611, 2020.

Article em En | MEDLINE | ID: mdl-32457834

Palavras-chave

immune checkpoint blockade; intralesional treatment; mucosal melanoma; primary resistance; talimogene laherparepvec

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google